Quest Diagnostics, a frontrunner in diagnostic information services, has just unveiled an innovative pharmacogenomic (PGx) laboratory test service. This cutting-edge service is designed to equip healthcare providers with crucial insights into individual genetic responses to specific drug therapies. By leveraging pharmacogenetics, providers can now make more informed decisions on medication selection and dosing across various medical specialties such as psychiatry, neurology, cardiology, oncology, rheumatology, pain management, and transplant medicine.
Unveiling the Power of Pharmacogenomics
Healthcare providers are increasingly realizing the significant role that genetics play in drug responses, particularly in scenarios involving multiple medications. Steven Keiles, Quest Diagnostics’ general manager for US Specialty Genetics and Genomics Services, emphasizes the importance of genetic insights in guiding prescription decisions and improving treatment outcomes. Through this new PGx offering in partnership with Coriell Life Sciences, providers can streamline prescription decisions, reduce trial-and-error approaches, and ultimately enhance patient outcomes.
Key Benefits of Quest Diagnostics’ PGx Offering
– Prevent therapeutic failure and Adverse Drug Interactions (ADIs)
– Avoid unnecessary drug costs and complications management
– Comprehensive testing of 17 genes and 4 HLA alleles
– Actionable pharmacogenetic associations validated by expert groups
Empowering Providers with Actionable Insights
Quest Diagnostics’ PGx service includes a detailed report featuring genotypes, predicted phenotypic responses, and personalized medication guidance through Coriell Life Sciences’ platform. Clinicians gain access to GeneDose LIVE, a clinical decision support tool that evaluates a patient’s therapeutic regimen, assessing genetic and non-genetic risks across prescribed medications. The dynamic recommendations provided are based on evidence-based gene-drug associations, ensuring precise and tailored treatment plans for each patient.
Enhancing Patient Care Through Genetic Insights
InformedDNA’s acquisition of Coriell Life Sciences underscores a commitment to translating genetic data into tangible health outcomes. Dr. Jeffrey Shaman, Vice President of Medical Affairs at InformedDNA, highlights the collaboration with Quest in delivering personalized care that optimizes treatment success and initial medication choices. By bridging genetics expertise with innovative technology, healthcare providers can now access a comprehensive medication risk management program that revolutionizes patient care.
Breakthrough in Precision Medicine
The acquisition of Coriell Life Sciences by InformedDNA signifies a monumental leap in precision medicine, amalgamating genetics expertise with scientific innovation in pharmacogenomics. This union aims to optimize clinical decisions, improve patient outcomes, and reduce healthcare costs through personalized genetic insights. With a vast team of board-certified genetics specialists, health organizations can tap into the latest genomics insights, facilitating informed clinical decisions and enhancing medication risk management protocols.
Accessible Testing for Enhanced Healthcare
Quest Diagnostics’ PGx testing is easily accessible through 2,000 patient service centers nationwide, allowing patients to undergo testing with a requisition from their healthcare provider. Additionally, the company offers convenient home collection services through at-home phlebotomy, catering to patients who face scheduling or distance constraints. This accessibility ensures that individuals can benefit from personalized genetic insights without added inconvenience.
Key Takeaways
– Pharmacogenomics testing offers personalized insights into drug responses
– Quest Diagnostics’ PGx service empowers providers with actionable recommendations
– Collaboration with InformedDNA and Coriell Life Sciences enhances precision medicine capabilities
– Accessible testing options ensure widespread adoption and improved patient outcomes
In conclusion, Quest Diagnostics’ launch of an advanced pharmacogenomics laboratory test service marks a significant milestone in personalized healthcare. By integrating genetic insights into medication decisions, healthcare providers can deliver tailored treatment plans, reduce adverse drug reactions, and enhance patient outcomes. The collaboration with InformedDNA and Coriell Life Sciences underscores a commitment to revolutionizing precision medicine and empowering providers with the tools to deliver individualized care. With accessibility at the forefront, Quest Diagnostics is paving the way for a healthier world through advanced genetic testing.
Read more on pharmabiz.com